A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Guselkumab (Primary) ; Secukinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ECLIPSE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 11 Jul 2018 Planned End Date changed from 23 Nov 2018 to 28 Sep 2018.
    • 15 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 16 May 2018 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top